The OvaCheck® Medical Advisory Board has been
established to provide ongoing guidance to Correlogic in the final
development of OvaCheck, and in its introduction to the medical and
patient communities. The board is comprised of pre-eminent medical
clinicians and researchers in gynecologic oncology, and is chaired
by one of the nation’s foremost authorities in gynecologic cancer,
Philip J. DiSaia, M.D. Dr. DiSaia is professor and director
of the Division of Gynecologic Oncology at the University of California
at Irvine, chairman of the Gynecologic Oncology Group, and the coauthor
of the leading medical textbook on gynecologic oncology.
Under Dr. DiSaia’s leadership, the board will review the full
scope of the test validation process and provide recommendations for
clinical use of the test to physicians, including guidance on appropriate
patient populations, frequency of testing, and interpretation of results. The
board will help present OvaCheck to the medical societies
and other organizations.
The expertise of this thought leader board will
contribute importantly to Correlogic’s goal of enabling OvaCheck to realize the full
potential of its breakthrough approach and technology – altering
the prognosis of ovarian cancer for the thousands of women diagnosed
with this disease each year.
